Literature DB >> 16986052

Pathophysiology of benign prostatic hyperplasia in the aging male population.

Herbert Lepor.   

Abstract

Nearly all men will develop histological benign prostatic hyperplasia by the age of 80, but the degree of prostatic enlargement resulting from the hyperplasia is highly variable. Historically, it has often been assumed that the pathophysiology of lower urinary tract symptoms (LUTS) in men is the result of bladder outlet obstruction associated with prostatic enlargement. The observation that prostatic enlargement, bladder outlet obstruction, and LUTS are all age-dependent has been interpreted to indicate that these phenomena were causally related, but there is insufficient evidence for this. Undoubtedly, some men' prostatic enlargement causes obstruction and symptoms. Based upon the available data, however, this subset appears to be extremely small. Because of the many urological and nonurological conditions that cause LUTS and age-dependent changes in bladder and neurological function, it is unlikely that there exists a single dominant etiology for the aging male population. If this is the case, then the optimal management of LUTS will require different and possibly combination therapies.

Entities:  

Year:  2005        PMID: 16986052      PMCID: PMC1477609     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  26 in total

1.  Radical retropubic prostatectomy reduces symptom scores and improves quality of life in men with moderate and severe lower urinary tract symptoms.

Authors:  E J Schwartz; H Lepor
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

2.  Natural history of prostatism: risk factors for acute urinary retention.

Authors:  S J Jacobsen; D J Jacobson; C J Girman; R O Roberts; T Rhodes; H A Guess; M M Lieber
Journal:  J Urol       Date:  1997-08       Impact factor: 7.450

3.  The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy.

Authors:  M Caine
Journal:  J Urol       Date:  1986-07       Impact factor: 7.450

Review 4.  Natural history of benign prostatic hyperplasia.

Authors:  S J Jacobsen; C J Girman; M M Lieber
Journal:  Urology       Date:  2001-12       Impact factor: 2.649

5.  Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia.

Authors:  M J Barry; A T Cockett; H L Holtgrewe; J D McConnell; S A Sihelnik; H N Winfield
Journal:  J Urol       Date:  1993-08       Impact factor: 7.450

6.  Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates.

Authors:  H Lepor; A Nieder; J Feser; C O'Connell; C Dixon
Journal:  Urology       Date:  1997-03       Impact factor: 2.649

7.  Neurally mediated hyperactive voiding in spontaneously hypertensive rats.

Authors:  J M Spitsbergen; D B Clemow; R McCarty; W D Steers; J B Tuttle
Journal:  Brain Res       Date:  1998-04-20       Impact factor: 3.252

8.  Autonomic receptors in human prostate adenomas.

Authors:  D I Gup; E Shapiro; M Baumann; H Lepor
Journal:  J Urol       Date:  1990-01       Impact factor: 7.450

9.  Anti-desmin vs. anti-actin for quantifying the area density of prostate smooth muscle.

Authors:  E Shapiro; V Hartanto; H Lepor
Journal:  Prostate       Date:  1992       Impact factor: 4.104

10.  The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.

Authors:  H Lepor; W O Williford; M J Barry; C Haakenson; K Jones
Journal:  J Urol       Date:  1998-10       Impact factor: 7.450

View more
  16 in total

Review 1.  Incontinence in the elderly, 'normal' ageing, or unaddressed pathology?

Authors:  William Gibson; Adrian Wagg
Journal:  Nat Rev Urol       Date:  2017-04-11       Impact factor: 14.432

2.  Age-related histological and zinc content changes in adult nonhyperplastic prostate glands.

Authors:  Vladimir Zaichick; Sofia Zaichick
Journal:  Age (Dordr)       Date:  2013-07-14

3.  Adenovirus-mediated delivery of shRNA against bFGF mRNA suppresses growth of cultured human primary prostatic stromal cells.

Authors:  Kai Wang; Linfeng Cheng; Yinghong Liang; Donghui Liu; Kai Li; Ping Wang
Journal:  Mol Biol Rep       Date:  2010-06-06       Impact factor: 2.316

Review 4.  Anatomy and Physiology of the Urinary Tract: Relation to Host Defense and Microbial Infection.

Authors:  Duane R Hickling; Tung-Tien Sun; Xue-Ru Wu
Journal:  Microbiol Spectr       Date:  2015-08

Review 5.  Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia.

Authors:  Youngjoo Kwon
Journal:  Food Sci Biotechnol       Date:  2019-04-17       Impact factor: 2.391

6.  Cost-effectiveness of dutasteride-tamsulosin combination therapy for the treatment of symptomatic benign prostatic hyperplasia: A Canadian model based on the CombAT trial.

Authors:  Afisi Ismaila; Anna Walker; Amyn Sayani; Bruno Laroche; J Curtis Nickel; John Posnett; Zhen Su
Journal:  Can Urol Assoc J       Date:  2013-06-12       Impact factor: 1.862

7.  Banana Flower Extract Suppresses Benign Prostatic Hyperplasia by Regulating the Inflammatory Response and Inducing G1 Cell-cycle Arrest.

Authors:  Liang-Chih Liu; Yung-Hsiang Lin; Ying-Chao Lin; Chi-Tang Ho; Chao-Ming Hung; Tzong-DER Way; DA-Tian Bau
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

8.  Effects of electroacupuncture on benign prostate hyperplasia patients with lower urinary tract symptoms: a single-blinded, randomized controlled trial.

Authors:  Jung-Sheng Yu; Kun-Hung Shen; Wen-Chi Chen; Jiann-Shyan Her; Ching-Liang Hsieh
Journal:  Evid Based Complement Alternat Med       Date:  2011-04-13       Impact factor: 2.629

9.  Elevated seminal plasma estradiol and epigenetic inactivation of ESR1 and ESR2 is associated with CP/CPPS.

Authors:  Florian Wagenlehner; Undraga Schagdarsurengin; Nils Nesheim; Stuart Ellem; Temuujin Dansranjavin; Christina Hagenkötter; Elena Berg; Rupert Schambeck; Hans-Christian Schuppe; Adrian Pilatz; Gail Risbridger; Wolfgang Weidner
Journal:  Oncotarget       Date:  2018-04-13

10.  Evaluation of apoptosis indexes in currently used oral alpha-blockers in prostate: a pilot study.

Authors:  Mehmet Demir; Yigit Akin; Kubra Asena Kapakin Terim; Mehmet Gulum; Evren Buyukfirat; Halil Ciftci; Ercan Yeni
Journal:  Int Braz J Urol       Date:  2018 May-Jun       Impact factor: 1.541

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.